Skin & Hair · Skin & Hair peptide (research)
Melanotan I
- Drug class
- Skin & Hair peptide (research)
- Status
- Compounded (503A)
- Also known as
- mt-1, mt1, melanotan 1, afamelanotide, scenesse, alpha-msh analog
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What Melanotan I is studied for
- Melanogenesis (research)
- Photoprotection research (research)
- EPP indication (afamelanotide, FDA-approved) (research)
Mechanism of action
Melanotan I is being studied in the skin & hair category. α-MSH analog (afamelanotide) studied for photoprotection and melanogenesis. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is Melanotan I?
Melanotan I is a skin & hair peptide. α-MSH analog (afamelanotide) studied for photoprotection and melanogenesis.
What is Melanotan I studied for?
Published research has examined Melanotan I for melanogenesis, photoprotection research, epp indication (afamelanotide, fda-approved). Human clinical evidence varies by indication.
Is Melanotan I FDA-approved?
No. Melanotan I is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is Melanotan I used in research?
Protocols vary by study. Melanotan I is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for Melanotan I is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.